Navigation Links
Sickle cell patients should be better monitored for constipation prevention
Date:6/16/2010

Not all patients with sickle cell disease receive laxatives after being treated with narcotics, despite recommendations from a collaborative panel of pediatric experts. These are the findings from a Nationwide Children's Hospital study examining patients from 29 pediatric hospitals, and appearing in Pediatric Blood & Cancer.

Narcotic-related adverse events are the most common adverse drug events in hospitalized children and constipation is a frequent narcotic-associated adverse drug event. In 2008, an expert panel of 14 freestanding children's hospitals met as part of the Reducing Narcotic-Related Adverse Drug Events in Children improvement collaborative and recommended that laxatives and stool softeners be proactively used when narcotics are prescribed.

Sickle cell disease patients are commonly prescribed narcotics to help manage vaso-occlusive pain crises, painful events that occur when blood flow is blocked to an area because the sickled cells have become stuck in small blood vessels. There are few studies discussing the impact of constipation on sickle cell disease and no studies have addressed the use of laxatives in these hospitalized patients.

"Besides causing discomfort to the patient, the development of constipation can negatively affect other aspects of inpatient care in patients with sickle cell disease," said Sarah O'Brien, MD, MSc, the study's lead author and principal investigator in the Center for Innovation in Pediatric Practice in The Research Institute at Nationwide Children's Hospital. "The abdomen is a well-known site of sickle cell pain. Abdominal pain due to constipation may be misinterpreted as a worsening vaso-occlusive crisis with subsequent higher doses of narcotics and therefore worsening constipation."

Dr. O'Brien, a hematologist in Hematology/Oncology and Blood & Marrow Transplantation at Nationwide Children's, and her colleagues used the Pediatric Health Information System, a multi-institutional, geographically diverse database to collect information on pediatric inpatients with sickle cell disease who received a narcotic medication during a 12-month period. They then investigated which of these patients received medications used to prevent and treat constipation during their hospitalization.

The study showed that one-third of sickle cell disease patients receiving narcotics were not prescribed concomitant laxatives or stool softeners as recommended by the Child Health Corporation of America quality improvement collaborative.

"We also discovered unexpected variability in the use of constipation medication," said Dr. O'Brien, also an assistant professor of Pediatrics at The Ohio State University College of Medicine. "While one would expect a diagnosis of constipation and increased length of stay to impact the use of laxatives, we also discovered that unrelated variables such as patient age, type of admission and hospital sickle cell disease patient volumes were associated with constipation medication use."

Older children were more likely to receive laxatives. Dr. O'Brien says that perhaps this is because they are better able to articulate symptoms of constipation. Patients with medical admissions were four times more likely to receive laxatives than patients with primarily surgical admission.

"Our findings demonstrate that increased attention needs to be paid to constipation prophylaxis in sickle cell patients, particularly in younger children and surgical admissions," said Dr. O'Brien.


'/>"/>

Contact: Mary Ellen Peacock
MaryEllen.Peacock@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. Stroke prevention study in children with sickle cell anemia, iron overload stopped early
2. NHLBI to hold workshop on health consequences of sickle cell trait
3. New study suggests sickle cell disease may affect brain function in adults
4. Sickle Cell Disease Tied to Cognitive Difficulties
5. Low blood oxygen may lead to heart defects in children with sickle cell disease
6. Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly
7. Cholesterol-Lowering Drug Shows Promise Against Serious Infections in Sickle Cell Disease
8. Statins Show Promise Against Sickle Cell
9. Blood stem-cell transplant regimen reverses sickle cell disease in adults
10. Bone Marrow Transplants May Cure Sickle Cell in Adults
11. New approach to sickle-cell disease shows promise in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... California (PRWEB) , ... January 23, 2017 , ... Old ... principles, has added Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team ... competing as a bodybuilder in 2012 and in less than a year was able ...
(Date:1/23/2017)... ... , ... “The Inn at the Mill”: a story of love and redemption, hope and ... happy and content. , “The Inn at the Mill” is the creation of published ... Vermont and is now living in Berks County on Crow Hill. The inn, ...
(Date:1/23/2017)... , ... January 23, 2017 , ... “Life Under Blankets”: ... depression from an early age. “Life Under Blankets” is the creation of published author, ... Illinois, Circle Campus in Chicago. She went on to pursue a master’s degree in ...
(Date:1/22/2017)... ... ... Phytocéane invites clients to take an exotic journey deep into the heart ... CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off the coast of ... to create this gentle, velvety body cream to envelop the skin in moisture while ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... Research and Markets has announced the addition of the ... (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, ... HIV/AIDS etc.), Forecast to 2022" report to their offering. ... US ... clinical lab testing, which has evolved as a major source ...
(Date:1/21/2017)... , Jan. 20, 2017  Today, ... Symposia Conference, "PI3K Pathways in Immunology, Growth ... (NASDAQ: INFI ) presented ... development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). ... to help overcome resistance to checkpoint inhibition ...
(Date:1/20/2017)... 2017 Research and Markets has announced ... Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company ... ... Hearing Aids Market Sales Volume, Company Analysis and Forecast to ... aid industry. The growing prevalence of hearing impairment ...
Breaking Medicine Technology: